Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options (Q38087529)

28 August 2017

title

Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options (English)

1 reference

chronic renal insufficiency

28 August 2017

0 references

1 reference

Erratum to: Pediatric Nephrology, Volume 29, Issue 5 (2014)

inferred from title

corrigendum / erratum

0 references

1

Damien Noone

1 reference

28 August 2017

Christoph Licht

2

1 reference

28 August 2017

publication date

8 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

29

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

779-792

1 reference

Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Economic burden of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Medical care costs associated with progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Mechanisms and treatment of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

How does proteinuria cause progressive renal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Cellular and molecular mechanisms of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Proteinuria: detection and role in native renal disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Tubulointerstitial injury and the progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Glomerular Proteinuria: A Complex Interplay Between Unique Players

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Screening for albuminuria identifies individuals at increased renal risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Review: renal protection by inhibition of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Strict blood-pressure control and progression of renal failure in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Randomized, double-blind, controlled study of losartan in children with proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Losartan and enalapril are comparable in reducing proteinuria in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Dual RAAS blockade is desirable in kidney disease: Con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Role of remission clinics in the longitudinal treatment of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Role of aldosterone in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone and glomerular podocyte injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Regression of existing glomerulosclerosis by inhibition of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The effect of aldosterone blockade in patients with Alport syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Are we ready to use aliskiren in children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

21 January 2018

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Pharmacological enhancement of the kallikrein-kinin system promotes anti-fibrotic responses in human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The endothelin system and its antagonism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

PPARγ and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The safety of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Rosiglitazone decreases albuminuria in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Telmisartan improves kidney function through inhibition of the oxidative phosphorylation pathway in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Telmisartan: just an antihypertensive agent? A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Heparanase in glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

New approaches to the treatment of dense deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Chemokines in renal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Addition of Angiotensin II Type 1 Receptor Blocker to CCR2 Antagonist Markedly Attenuates Crescentic Glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Pentoxifylline in preterm neonates: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effect of pravastatin on nephroprotection in deoxycorticosterone acetate-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Statins in hypertension: are they a new class of antihypertensive agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Statins and blood pressure regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Do HMG-CoA reductase inhibitors improve kidney function? The saga continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

New clinical trials with vitamin D and analogs in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor- Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2436-5

Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension

21 January 2018

1 reference

12 December 2020

Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study

1 reference

12 December 2020

Can vitamin D slow down the progression of chronic kidney disease?

1 reference

12 December 2020

Vasopeptidase inhibitors

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor

1 reference

12 December 2020

Blood pressure and end-stage renal disease in men

1 reference

12 December 2020

Prevalence of complications in children with chronic kidney disease according to KDOQI

1 reference

12 December 2020

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts

1 reference

12 December 2020

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis

1 reference

12 December 2020

Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease

1 reference

12 December 2020

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

12 December 2020

Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition

1 reference

12 December 2020

Glomerular filtration: the charge debate charges ahead

1 reference

12 December 2020

Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.

1 reference

12 December 2020

Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy

1 reference

12 December 2020

Tubular toxicity of proteinuria

1 reference

12 December 2020

Heparanase activity is dysregulated in children with steroid-sensitive nephrotic syndrome

1 reference

12 December 2020

The effect of protein restriction on the progression of renal insufficiency

1 reference

12 December 2020

Effects of pioglitazone on renal calcium excretion

1 reference

12 December 2020

Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis

1 reference

12 December 2020

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria

1 reference

12 December 2020

Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury

1 reference

12 December 2020

PPAR-gamma agonist protects podocytes from injury

1 reference

12 December 2020

Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease

1 reference

12 December 2020

Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688

1 reference

12 December 2020

Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation

1 reference

12 December 2020

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

12 December 2020

Molecular Basis of Proteinuria of Glomerular Origin

1 reference

12 December 2020

The role of statins in chronic kidney disease

1 reference

12 December 2020

Effects of atorvastatin on carotid intima media thickness: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening

1 reference

12 December 2020

Sulodexide for diabetic nephropathy: another one bites the dust

1 reference

12 December 2020

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease

1 reference

12 December 2020

Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children

1 reference

12 December 2020

Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered

1 reference

12 December 2020

10.1007/S00467-013-2436-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1048633765

0 references

1 reference